|
Walter Curran, MD, FACR, FASCO |
CV
|
Executive Director, Winship Cancer Institute of Emory University, USA
Progress through the new American NCI National Clinical Trials Network:
NRG Oncology as a case study
|
|
|
Thomas Gajewski, MD, PhD
|
CV
|
Professor, University of Chicago, USA
Tumor and host factors regulating immunotherapy efficacy versus resistance
|
|
|
Yeul Hong Kim, MD, PhD
|
CV
|
Professor, Korea University College of Medicine, Korea
The complex path to cancer precision medicine
|
|
|
Sanghyuk Lee, PhD |
CV
|
Professor, Department of Life Science, Ewha Womans University, Korea
Integrative cancer genomics for precision medicine in lung cancer
|
|
Educational Sessions (ES)
ES1. Clinical oncology for basic scientists
6/20(T), 09:00-10:40
cv
Kyu-Rae Kim
University of Ulsan College of Medicine
cv
Kyung Won Kim
University of Ulsan College of Medicine
cv
Inkeun Park
Gachon University College of Medicine
cv
Yoon Ji Choi
Korea University College of Medicine
ES2. Recent advances in understanding and treating advanced
GI cancer
6/20(T), 09:00-10:40
cv
Sang-Hoon Ahn
Seoul National University College of Medicine
cv
Sun Jin Park
Kyung Hee University College of Medicine
cv
Hye Jin Kim
Kyungpook National University School of Medicine
cv
Jong-Han Kim
Korea University College of Medicine
ES3. Optimal combination of radiation therapy and immune
checkpoint blockades
6/20(T), 09:00-10:40
cv
SaeGwang Park
Inje University College of Medicine
cv
Jinho Kim
Seoul National University College of Medicine
cv
Kyong Hwa Park
Korea University College of Medicine
Young Investigator Symposium (YIS)
YIS1. Korean Young Investigator Symposium
6/20(T), 09:00-10:40
cv
Jae-Young Kim
Chungnam National University
cv
Han Sang Kim
Yonsei University College of Medicine
cv
Jiheum Paek
Ajou University School of Medicine
cv
HaeYun Jung
Sungkyunkwan University School of Medicine
YIS2. Overseas Young Investigator Symposium
6/21(F), 09:00-10:00
cv
Dong Hyuk Ki
Harvard Medical School/Dana-Farber Cancer Institute, USA
cv
Daniel Sanghoon Shin
David Geffen School of Medicine at UCLA, USA
cv
Youngwook Won
University of Arizona College of Medicine, USA
SP01. Conquering stomach cancer, the major
cancer killer
in Korea and Japan
6/20(T), 13:20-15:00
cv
Toshikazu Ushijima
National Cancer Center Research Institute, Japan
cv
Daehee Hwang
Seoul National University School of Biological Sciences
cv
Yoku Hayakawa
The University of Tokyo, Japan
cv
Hoon Hur
Ajou University School of Medicine
SP02. Tissue agnostic drug development
6/20(T), 13:20-15:00
cv
Kenneth Emancipator
MSD, USA
cv
Nicoletta Brega
Bayer, Italy
cv
Myung-Ju Ahn
Sungkyunkwan University School of Medicine
SP03. Updates on head and neck-thyroid oncology
6/20(T), 13:20-15:00
cv
Xiaolei Wang
The Cancer Institute and Hospital, Chinese Academy of Medical Sciences, China
cv
Lai-ping Zhong
Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, China
cv
Chul-Ho Kim
Ajou University School of Medicine
cv
Young Joo Park
Seoul National University College of Medicine
SP04. Immunotherapy for rare cancer
6/20(T), 13:20-15:00
cv
Robbie G. Majzner
Stanford University School of Medicine, USA
cv
Yasushi Fuchimoto
International University of Health and Welfare School of Medicine, Japan
cv
Chang-Yuil Kang
Seoul National University College of Pharmacy
SP05. Strategic plans of improving
multicenter clinical trials
6/20(T), 13:20-15:00
cv
Chel Hun Choi
Sungkyunkwan University School of Medicine
cv
Yong Wha Moon
CHA University School of Medicine
cv
Won Park
Sungkyunkwan University School of Medicine
cv
Sokbom Kang
National Cancer Center
SP06. Vascular regulation of cancer
progression
6/20(T), 13:20-15:00
cv
Ho Jeong Kwon
Yonsei University
cv
Andreas Fischer
German Cancer Research Center (DKFZ), Germany
cv
Jeong Ho Lee
Korea Advanced Institute of Science and Technology
cv
Injune Kim
Korea Advanced Institute of Science and Technology
SP07. Current status of precision medicine
in colorectal cancer
6/20(T), 15:20-17:00
cv
Hideo Baba
Graduate School of Medical Sciences, Kumamoto University, Japan
cv
Toshifumi Wakai
Niigata University Graduate School of Medical and Dental Sciences, Japan
cv
Jihun Kim
University of Ulsan College of Medicine
cv
Jin Won Kim
Seoul National University Bundang Hospital
SP08. Advanced and innovative clinical
research
6/20(T), 15:20-17:00
cv
Edward Kim
Atrium Health Levine Cancer Institute, USA
cv
Seung-June Oh
Seoul National University College of Medicine
cv
Jee Hyun Kim
Seoul National University College of Medicine
SP09. Recent precision medicine in
gynecologic and breast cancer
6/20(T), 15:20-17:00
cv
Myong Cheol Lim
National Cancer Center
cv
Min Chul Choi
CHA University School of Medicine
cv
Sung Jong Lee
The Catholic University of Korea College of Medicine
cv
Hyung Seok Park
Yonsei University College of Medicine
cv
Woong Ju
Ewha Womans University College of Medicine
SP10. Omics for innovative clinical
cancer research
6/20(T), 15:20-17:00
cv
Minho Lee
The Catholic University of Korea
cv
Mirang Kim
Korea Research Institute of Bioscience & Biotechnology
cv
Wonshik Han
Seoul National University College of Medicine
cv
Hyun Goo Woo
Ajou University School of Medicine
SP11. Exchange and cooperation of
oncology between South and North Korea
6/20(T), 15:20-17:00
cv
Sin Gon Kim
Korea University College of Medicine
cv
Hee Young Shin
Seoul National University College of Medicine
cv
Yoonsang Lee
Nanum International
SP12. Basic immunology: (Treatment-resistant) Tumor microenvironment
6/21(F), 13:40-15:20
cv
Hun Sik Kim
University of Ulsan College of Medicine
cv
Seung Hyeok Seok
Seoul National University College of Medicine
cv
Tae-Woo Kim
Korea University College of Medicine
SP13. Immune targeted biomarkers in
therapeutic decision making
6/21(F), 13:40-15:20
cv
Kyu Sang Lee
Seoul National University College of Medicine
cv
Hyunki Kim
Yonsei University College of Medicine
cv
Jung Ho Kim
Seoul National University Hospital
cv
Tae-Min Kim
The Catholic University of Korea College of Medicine
SP14. Promising anti-cancer drug pipeline
in pre-clinical and clinical stages in Korea
6/21(F), 13:40-15:20
cv
SungKu Choi
Ildong Pharmaceutical
SP15. Tumor microenvironment of solid
cancer
6/21(F), 13:40-15:20
cv
Semin Lee
Ulsan National Institute of Science and Technology
cv
Darren Reece Williams
Gwangju Institute of Science and Technology
cv
Atsushi Enomoto
Nagoya University, Japan
cv
Chan Kim
CHA University School of Medicine
SP16. Underlying mechanisms of novel cellular therapies
6/21(F), 15:40-17:20
cv
Chantale Bernatchez
MD Anderson Cancer Center, USA
cv
Cara Haymaker
MD Anderson Cancer Center, USA
cv
Chan-Young Ock
Seoul National University Hospital
SP17. Microbiology and microbiome in
cancer
6/21(F), 15:40-17:20
cv
Dong-Gun Lee
The Catholic University of Korea College of Medicine
cv
Ju Sun Song
Green Cross Genome
cv
Hansoo Park
Gwangju Institute of Science and Technology
SP18. Current practice and dilemma in
oligometastatic disease of
lung cancer
6/21(F), 15:40-17:20
cv
Dong Hoon Shin
Pusan National University School of Medicine
cv
Hyun Koo Kim
Korea University College of Medicine
cv
Yang-Gun Suh
National Cancer Center
cv
Sook Hee Hong
The Catholic University of Korea College of Medicine
SP19. ¾Ï°ü·ÃÇÐȸÇùÀÇü ½ÉÆ÷Áö¾ö
6/21(F), 15:40-17:20
cv
Jung Hye Kwon
Hallym University College of Medicine
cv
Dae Ho Lee
University of Ulsan College of Medicine
cv
Ji Soo Park
Yonsei University College of Medicine
MC1. Recent updates in the development of immune-therapy for cancer treatment
6/20(T), 13:20-15:00
cv
Wallace Mondesire
MSD, USA
cv
Tae-Min Kim
The Catholic
University of Korea
College of Medicine
cv
Victoria Robinson
MSD, USA
MC2. GC academy- Special talk for antiangiogenic agents in mGC treatment
6/20(T), 15:20-17:00
cv
Jin-Soo Kim
Seoul National University Boramae Medical Center
cv
Sun Young Rha
Yonsei University College of Medicine
cv
Keun-Wook Lee
Seoul National University College of Medicine
MC3. How to generate and utilize RWE (real-world evidence) in oncology
6/21(F), 13:40-15:20
cv
Dae Ho Lee
University of Ulsan College of Medicine
cv
Ju-Young Shin
Sungkyunkwan University School of Pharmacy
Camille Perret
Roche, Switzerland
Luncheon Symposium 1 (Sanofi Genzyme)
6/20(T), 12:20-13:20
|
Julien Taieb |
CV
|
Georges Pompidou European Hospital, Sorbonne Paris-Cite, Universite Paris-Descartes, France
Individualized treatment decision for optimal sequence in mCRC, with aflibercept
|
|
Luncheon Symposium 2 (Servier)
6/20(T), 12:20-13:20
|
Changhoon Yoo |
CV
|
University of Ulsan College of Medicine
Liposomal irinotecan, new hope for the treatment of metastatic pancreatic cancer
|
|
Luncheon Symposium 3 (AstraZeneca)
6/20(T), 12:20-13:20
|
Tae Min Kim |
CV
|
Seoul National University College of Medicine
Cutting-edge front-line treatment for advanced non-small cell lung cancer
|
|
Luncheon Symposium 4 (Pfizer)
6/20(T), 12:20-13:20
|
Takashi Seto |
CV
|
Kyushu Cancer Center, Japan
Therapeutic strategy for maximizing overall survival for ALK/ROS1+ NSCLC
|
|
Luncheon Symposium 5 (MSD)
6/21(F), 11:50-12:50
|
Ji Hyun Park |
CV
|
Konkuk University School of Medicine
'Standard of Care' to 'Standard of Survival': Unfolding the quantum leap in mNSCLC
|
|
Luncheon Symposium 6 (Roche)
6/21(F), 11:50-12:50
|
Ji-Youn Han |
CV
|
National Cancer Center
The evolving power of immunotherapy: Atezolizumab in advanced lung cancer
|
|
Luncheon Symposium 7 (Lilly)
6/21(F), 11:50-12:50
|
Keun-Wook Lee |
CV
|
Seoul National University College of Medicine
An optimal post-progression treatment option to improve advanced gastric cancer patient outcomes: Clinical experiences with ramucirumab
|
|
top